sildenafil-citrate and Prostatitis

To investigate the value of sildenafil in the treatment of prostatitis-related sexual dysfunction.. Two hundred and eighty patients with chronic prostatitis complicated by sexual dysfunction were radomized into two groups, on treated with sildenafil, and the other with Quinolone. Results were analyzed by comparing the chronic prostatitis symptoms (CPSI score), sexual dysfunction symptoms (PSFI score) and anxiety symptoms (SAS score) between pre-treatment and post-treatment groups.. The degree of prostatitis-related sexual dysfunction was not correlated with that of prostatitis symptoms. The prostatitis symptoms and sexual function were improved after sildenafil treatment compared with the control (P < 0.05), and anxiety score after treatment was significantly lower than the control (P < 0.05).. Sildenafil not only works on prostatitis-related sexual dysfunction but also improves the symptoms of prostatitis and anxiety.

Topics: Adult; Anxiety; Humans; Male; Middle Aged; Piperazines; Prostatitis; Purines; Sexual Dysfunctions, Psychological; Sildenafil Citrate; Sulfones

We evaluated the effectiveness of tamsulosin monotherapy versus tamsulosin plus sildenafil combination therapy on erectile dysfunction (ED) in young patients with type III chronic prostatitis and ED by using symptom score scales.. 44 male patients were divided into 2 groups: the first group (20 patients) was treated with tamsulosin 0,4 mg monotherapy and the second one 24 patients) was treated with tamsulosin 0,4 mg plus sildenafil 50 mg combination therapy. “International Prostate Symptom Score, “National Institute of Health Chronic Prostatitis Symptom Index" (NIH-CPSI) and “International Index of Erectile Function" (IIEF-5) were investigated in each group of patients, and scores calculated during the first medical examination. Both groups were treated with tamsulosin once daily for 60 days, while sildenafil 50 mg was given on demand (at least 2 times per week) for 60 days. During the second medical examination IPSS, NIH-CPSI and IIEF-5 scores were analyzed once more. Afterwards, the alterations of scores among medical examinations in each group and between both groups were statistically compared.. The age average of the 44 cases included was 32.04 3.15 years. Both groups present a statistically significant decrease, between the first and the second medical examination, in IPSS, NIH-CPSI scores and statistically significant increase in IIEF-5 score. In addition, there is no statistically significant difference, in all scores, between mono and combination therapy.. tamsulosin monotherapy, as well as a combination therapy (tamsulosin plus sildenafil) has an improving effect on symptoms and on ED in patients with type III prostatitis. In the near future alpha-blockers monotherapy could be used in the treatment of chronic prostatitis and ED cases instead of phosphodiesterase type 5 (PDE-5) inhibitors combination therapy.

Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Chronic Disease; Drug Therapy, Combination; Erectile Dysfunction; Humans; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Prostatitis; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Tamsulosin; Young Adult

To explore the efficacy of sildenafil on erectile dysfunction (ED) of newlyweds, the author studied 60 outpatients within a month of marriage, who suffered from sexual intercourse (SI) failure caused by ED and showed no improvement after receiving sex education and psychological consultation. The patients were given oral sildenafil, 100 mg for the first and second times, 50 mg for the third and fourth times, no more than once every day, with a 1- to 3-day break between every two times. Four times of sildenafil administration formed one course of treatment. Sildenafil was taken 1 h before SI and was aided with adequate sexual stimulation. The rates of successful SI due to improved erection during and after a course of sildenafil treatment were 93.3% (56/60) and 85% (51/60), both P > 0.05. In the groups with one and more than one SI failure the successful SI rates after a sildenafil treatment course were 93.1% (27/29) and 77.4% (24/31), both P > 0.05. Oral sildenafil with psychological therapy in the treatment of ED of newlyweds proves to be effective in restoring the patients' sexual function and relieving their mental pressure or stress.

Topics: Adult; Chronic Disease; Erectile Dysfunction; Humans; Male; Marriage; Phosphodiesterase Inhibitors; Piperazines; Prostatitis; Purines; Sildenafil Citrate; Sulfones; Time Factors; Treatment Outcome; Young Adult

Chronic prostatitis is a common urological complaint without clearly defined causation or definitive treatment.. Phosphodiesterase 5 (PDE5) Inhibitor mediated relaxation of prostatic duct smooth muscle increases washout of prostatic reflux products reducing prostatic inflammation and consequent prostatitis symptoms. RATIONALE OF HYPOTHESIS: The presence of both Nitric Oxide Synthase and Phosphodiesterase 5 in human prostatic tissue and the effect of nitric oxide donors and PDE5 inhibitors in vitro indicate PDE5 inhibitors relax prostatic smooth muscle. Significant retrograde urinary flux into prostatic ducts has been described and suggested as the mechanism of chronic prostatitis. We postulate PDE5 inhibitors alter prostatic reflux hence prostatitis symptoms.. PDE5 inhibitors may represent a simple, effective treatment for chronic prostatitis.

Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Humans; Imidazoles; Immunity, Innate; Male; Models, Immunological; Nitric Oxide; Phosphodiesterase Inhibitors; Piperazines; Prostate; Prostatitis; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride